NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX
Post# of 148
(Total Views: 49)
Posted On: 10/07/2025 4:44:53 PM
NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Reports Positive Safety Review from DMC in Ongoing Phase 3 FLASH2 Study of HyBryte for CTCL
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing treatments for rare diseases, announced that its Data Monitoring Committee has completed its first review of the confirmatory Phase 3 FLASH2 study of HyBryte(TM) (synthetic hypericin) in cutaneous T-cell lymphoma, concluding there are no safety concerns and that the therapy maintains an acceptable safety profile consistent with prior trials. Enrollment is progressing on schedule, with an update expected in Q4 2025 and a blinded interim efficacy analysis planned for 1H 2026. The FLASH2 trial builds on the Company’s earlier statistically significant Phase 3 results and additional supportive studies demonstrating HyBryte’s efficacy and tolerability as a potential first-line treatment option for early-stage CTCL.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing treatments for rare diseases, announced that its Data Monitoring Committee has completed its first review of the confirmatory Phase 3 FLASH2 study of HyBryte(TM) (synthetic hypericin) in cutaneous T-cell lymphoma, concluding there are no safety concerns and that the therapy maintains an acceptable safety profile consistent with prior trials. Enrollment is progressing on schedule, with an update expected in Q4 2025 and a blinded interim efficacy analysis planned for 1H 2026. The FLASH2 trial builds on the Company’s earlier statistically significant Phase 3 results and additional supportive studies demonstrating HyBryte’s efficacy and tolerability as a potential first-line treatment option for early-stage CTCL.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)